NASDAQ : LKFT
Lakefront Biotherapeutics NV — Key statistics
Belgium
Last price 32.23 USD (Oct 30, 2026, 1:55 PM EDT) · Market cap 2.06B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.07B |
| Enterprise Value | -426.24M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 65.66M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 30.52% |
| Float | 22.51M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 3.19 |
| Forward PE | n/a |
| PS Ratio | 1.83 |
| Forward PS | 11.44 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 32.84 |
| Quick Ratio | 32.65 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | n/a |
| Interest Coverage | 664.53 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 20.12% |
| Return on Assets (ROA) | 9.93% |
| Return on Invested Capital (ROIC) | 87.08% |
| Return on Capital Employed (ROCE) | 17.36% |
| Weighted Average Cost of Capital (WACC) | 4.59% |
| Revenue Per Employee | $5.77M |
| Profits Per Employee | $3.48M |
| Employee Count | 196 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 15.16 |
Taxes
| Measure | Value |
|---|
| Income Tax | -19.07M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +4.40% |
| 50-Day Moving Average | 29.49 |
| 200-Day Moving Average | 29.92 |
| Relative Strength Index (RSI) | 69.78 |
| Average Volume (20 Days) | 264,199 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.42M |
| Short Previous Month | 3.32M |
| Short % of Shares Out | 3.50% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.95 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.13B |
| Gross Profit | 765.17M |
| Operating Income | 650.63M |
| Pretax Income | 659.92M |
| Net Income | 681.64M |
| EBITDA | 649.97M |
| EBIT | 650.63M |
| Earnings Per Share (EPS) | $10.11 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.56B |
| Total Debt | 7.27M |
| Net Cash | 2.55B |
| Net Cash Per Share | $38.86 |
| Equity (Book Value) | 3.73B |
| Book Value Per Share | 56.79 |
| Working Capital | 2.56B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -253.39M |
| Capital Expenditures | -5.14M |
| Depreciation & Amortization | -648,815 |
| Net Borrowing | -3.62M |
| Free Cash Flow | -258.54M |
| FCF Per Share | -$3.94 |
Margins
| Measure | Value |
|---|
| Gross Margin | 67.61% |
| Operating Margin | 57.49% |
| Pretax Margin | 58.31% |
| Profit Margin | 60.23% |
| EBITDA Margin | 57.43% |
| EBIT Margin | 57.49% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | -0.05% |
| Earnings Yield | 31.31% |
| FCF Yield | -12.51% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $30.31 |
| Price Target Difference | -6.10% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | -70.19% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 13.92 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |